CARM
Income statement / Annual
Last year (2024), Carisma Therapeutics, Inc.'s total revenue was $19.63 M,
an increase of 31.59% from the previous year.
In 2024, Carisma Therapeutics, Inc.'s net income was -$60.48 M.
See Carisma Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$19.63 M |
$14.92 M |
$9.83 M |
$26.54 M |
$11.24 M |
$0.00 |
$0.00 |
$425.00 K |
$29.98 M |
$990.00 K |
| Cost of Revenue |
$59.67 M
|
$74.13 M
|
$0.00
|
$85.00 K
|
$0.00
|
$219.00 K
|
$208.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$40.04 M
|
-$59.21 M
|
$9.83 M
|
$26.46 M
|
$11.24 M
|
-$219.00 K
|
-$208.00 K
|
$425.00 K
|
$29.98 M
|
$990.00 K
|
| Gross Profit Ratio |
-2.04
|
-3.97
|
1
|
1
|
1
|
0
|
0
|
1
|
1
|
1
|
| Research and Development Expenses |
$59.67 M
|
$74.13 M
|
$56.62 M
|
$25.23 M
|
$23.29 M
|
$24.44 M
|
$13.87 M
|
$12.23 M
|
$12.20 M
|
$25.97 M
|
| General & Administrative Expenses |
$20.14 M
|
$29.53 M
|
$9.38 M
|
$0.00
|
$5.09 M
|
$12.21 M
|
$11.62 M
|
$8.07 M
|
$14.74 M
|
$9.85 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$170.00 K
|
-$3.30 M
|
$0.00
|
| Selling, General & Administrative Expenses |
$20.14 M
|
$29.53 M
|
$9.38 M
|
$29.39 M
|
$5.09 M
|
$12.21 M
|
$11.62 M
|
$7.90 M
|
$11.44 M
|
$9.85 M
|
| Other Expenses |
-$57.67 M
|
-$74.13 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$22.14 M
|
$29.53 M
|
$66.00 M
|
$54.62 M
|
$28.38 M
|
$36.65 M
|
$25.49 M
|
$20.13 M
|
$23.64 M
|
$35.82 M
|
| Cost And Expenses |
$81.81 M
|
$103.65 M
|
$66.00 M
|
$54.71 M
|
$28.38 M
|
$36.87 M
|
$25.70 M
|
$20.41 M
|
$23.82 M
|
$36.19 M
|
| Interest Income |
$1.70 M
|
$1.94 M
|
$0.00
|
$10.00 K
|
$29.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$3.15 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$247.00 K
|
$1.40 M
|
| Depreciation & Amortization |
$3.35 M
|
$2.84 M
|
$1.89 M
|
$85.00 K
|
$122.00 K
|
$219.00 K
|
$208.00 K
|
$285.00 K
|
$178.00 K
|
$366.00 K
|
| EBITDA |
-$56.83 M |
-$85.89 M |
-$56.19 M |
-$8.52 M |
-$27.93 M |
-$107.28 M |
-$33.49 M |
-$28.74 M |
$2.32 M |
-$31.69 M |
| EBITDA Ratio |
-2.89
|
-5.76
|
-5.71
|
-0.32
|
-2.49
|
0
|
0
|
-67.63
|
0.08
|
-32.01
|
| Operating Income Ratio |
-3.17
|
-5.95
|
-5.71
|
-1.06
|
-2.53
|
0
|
0
|
-47.02
|
0.21
|
-35.55
|
| Total Other Income/Expenses Net |
$1.70 M
|
$1.85 M
|
-$5.06 M
|
$19.55 M
|
$29.00 K
|
-$70.63 M
|
-$7.99 M
|
-$9.04 M
|
-$4.27 M
|
$1.74 M
|
| Income Before Tax |
-$60.48 M
|
-$86.88 M
|
-$61.23 M
|
-$8.61 M
|
-$28.35 M
|
-$107.50 M
|
-$33.69 M
|
-$29.03 M
|
$1.90 M
|
-$33.45 M
|
| Income Before Tax Ratio |
-3.08
|
-5.82
|
-6.23
|
-0.32
|
-2.52
|
0
|
0
|
-68.3
|
0.06
|
-33.79
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
-$8.27 M
|
$0.00
|
$0.00
|
$46.86 K
|
$0.00
|
$5.00 K
|
$0.00
|
| Net Income |
-$60.48 M
|
-$86.88 M
|
-$61.23 M
|
-$336.00 K
|
-$28.35 M
|
-$107.50 M
|
-$33.69 M
|
-$29.03 M
|
$1.89 M
|
-$33.45 M
|
| Net Income Ratio |
-3.08
|
-5.82
|
-6.23
|
-0.01
|
-2.52
|
0
|
0
|
-68.3
|
0.06
|
-33.79
|
| EPS |
-1.46 |
-2.59 |
-1.52 |
-1.01 |
-0.7 |
-23.64 |
-10.91 |
-22.24 |
1.79 |
-35.23 |
| EPS Diluted |
-1.46 |
-2.59 |
-1.52 |
-1.01 |
-0.7 |
-23.64 |
-10.91 |
-22.24 |
1.74 |
-35.23 |
| Weighted Average Shares Out |
$41.46 M
|
$33.52 M
|
$40.26 M
|
$9.12 M
|
$5.91 M
|
$4.55 M
|
$3.09 M
|
$1.31 M
|
$1.05 M
|
$949.65 K
|
| Weighted Average Shares Out Diluted |
$41.46 M
|
$33.52 M
|
$40.26 M
|
$9.12 M
|
$5.91 M
|
$4.55 M
|
$3.09 M
|
$1.31 M
|
$1.09 M
|
$949.65 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
